Linked Life Data

20371451

Source:http://linkedlifedata.com/resource/pubmed/id/20371451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-4-7
pubmed:abstractText
Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications have been rarely described. Herein, we present a case of rapid fatal pulmonary complications in a patient with ALK-negative anaplastic large-cell lymphoma after receiving a treatment with bortezomib.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
2152-2669
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
152-4
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
pubmed:affiliation
Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
pubmed:publicationType
Journal Article, Case Reports